Abiopharma

🔍 Sylvain Jereme M (Executive)

Company: DEXCOM INC (DXCM)

Report Date: 2026-03-08

Detailed Transactions and Holdings:

• Acquired 48,774 shares of Common Stock (Direct)
  Date: 2026-03-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 172,242.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 18,950 shares of Common Stock at $68.1 per share (Direct)
  Date: 2026-03-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 153,292.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
• F2: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.
• F3: Included in this number are 92,794 unvested RSUs, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 261 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.